QLINEA Q-linea AB (publ)
Q-linea AB (publ) engages in the manufacturing and sale of instruments and consumables diagnose and treat infectious diseases in the United Kingdom, the United States, France, the Middle East, Belgium, Italy, and Finland. It offers ASTar, an antimicrobial susceptibility testing (AST) technology used in the treatment of bloodstream infections and sepsis; and ASTar BC G- Kit which contains two disposables, including a sample preparation cartridge and an AST disc, used with the Frozen insert. The company also develops Podler, a portable blood culture technology. It serves physicians, hospitals, laboratories, healthcare payers, and the medical profession. The company was incorporated in 2007 and is headquartered in Uppsala, Sweden.…
Industry Peers
Medical DevicesKey Statistics
About Q-linea (STO: QLINEA)
›
Q-linea (STO: QLINEA) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 66 employees.
The shares were at 11.35 SEK on 19 November 2026, down 54.5% over 52 weeks. Its 52-week range is 10.80 SEK to 38.42 SEK: the price is 70.5% below the high and 5.1% above the low.
Its market capitalisation is 215.07M SEK.
Q-linea reports return on equity of -54.0% and revenue up 38.2% year over year.
It holds more cash than debt, a net cash position of 133.85M SEK. Its Piotroski F-score is 6 out of 9, an average reading of its financial health.